Rapport Therapeutics, Inc. RAPP EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s EPS (diluted)?
- Rapport Therapeutics, Inc. (RAPP) reported EPS (diluted) of -$0.42 in Q1 2026.
- How has Rapport Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Rapport Therapeutics, Inc.'s EPS (diluted) increased by 38.2% year-over-year, from -$0.68 to -$0.42.
- What is the long-term trend for Rapport Therapeutics, Inc.'s EPS (diluted)?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s EPS (diluted) has grown at a -64.9% compound annual growth rate (CAGR), from -$23.10 to -$2.85.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.